BIOATLA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
BIOATLA, INC. (BCAB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.65% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-31
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 3.82%, a 0.78% decline year-over-year.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.85%, a 640.38% increase year-over-year.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 0.52%, a 0.00% change year-over-year.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2021-03-31 was 0.52%.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.65%, a 14.12% decline from fiscal 2024.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.25%, a 9.25% increase from fiscal 2023.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.89%, a 81.78% increase from fiscal 2022.
- BIOATLA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.14%, a 101.89% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | 3.65% 10-K · filed 2026-03-31 | |||||
| 2024-12-31 | 4.25% 10-K · filed 2026-03-31 | |||||
| 2024-09-30 | 4.25% 10-Q · filed 2024-11-07 | |||||
| 2024-06-30 | 4.39% 10-Q · filed 2024-08-08 | |||||
| 2024-03-31 | 3.82% 10-Q · filed 2024-05-14 | |||||
| 2023-12-31 | 3.89% 10-K · filed 2025-03-28 | |||||
| 2023-09-30 | 3.88% 10-Q · filed 2024-11-07 | |||||
| 2023-06-30 | 3.86% 10-Q · filed 2024-08-08 | |||||
| 2023-03-31 | 3.85% 10-Q · filed 2024-05-14 | |||||
| 2022-12-31 | 2.14% 10-K · filed 2024-03-26 | |||||
| 2022-09-30 | 2.05% 10-Q · filed 2023-11-07 | 2.09% 10-Q · filed 2022-11-04 | ||||
| 2022-06-30 | 2.05% 10-Q · filed 2023-08-01 | |||||
| 2022-03-31 | 0.52% 10-Q · filed 2023-05-11 | 1.88% 10-Q · filed 2022-05-05 | ||||
| 2021-12-31 | 1.06% 10-K · filed 2023-03-23 | |||||
| 2021-09-30 | 0.99% 10-Q · filed 2022-11-04 | |||||
| 2021-06-30 | 0.98% 10-Q · filed 2022-08-09 | |||||
| 2021-03-31 | 0.52% 10-Q · filed 2022-05-05 | 52.00% 10-Q · filed 2021-05-12 | ||||
| 2020-12-31 | 0.52% 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |